GleamWall
中文EN

ZTS Zoetis Inc.

Pharmaceutical Preparations · NYSE · SEC CIK 1555280 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1.0%
TTM net income YoY-5.5%
TTM EPS YoY0.7%
Revenue 3-yr CAGR4.3%
Net income 3-yr CAGR2.9%

Margins

Gross margin71.4%
Operating margin—
Net margin26.1%
FCF margin24.0%
EBITDA margin—

Returns

ROE57.1%
ROA16.4%
ROIC (approx.)—
Asset turnover0.63x

Leverage & solvency

Liabilities / assets78.1%
Debt / equity2.74x
Current ratio2.35x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue5.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$2.39B$2.47B$2.26B$2.39B$2.42B$2.47B$2.20B$2.32B
Cost of revenue$698.00M$673.00M$641.00M$712.00M$697.00M$664.00M$618.00M$707.00M
Gross profit$1.69B$1.79B$1.62B$1.68B$1.73B$1.81B$1.58B$1.61B
R&D expense$174.00M$173.00M$180.00M$199.00M$175.00M$166.00M$162.00M$186.00M
SG&A expense$582.00M$592.00M$588.00M$619.00M$582.00M$614.00M$574.00M$625.00M
Interest expense$62.00M$61.00M$62.00M$57.00M$58.00M$53.00M$54.00M$51.00M
Pretax income$729.00M$866.00M$758.00M$761.00M$886.00M$912.00M$773.00M$732.00M
Income tax$138.00M$175.00M$157.00M$158.00M$165.00M$186.00M$171.00M$151.00M
Net income$591.00M$691.00M$601.00M$603.00M$721.00M$726.00M$602.00M$581.00M
EPS (basic)1.441.651.42—1.631.631.34—
EPS (diluted)1.441.651.42—1.631.631.34—
Dividends declared per share0.000.530.531.030.000.500.500.93
Weighted avg. shares (diluted)411.60M417.70M422.40M—443.20M445.50M448.00M—
Balance sheet
Cash & equivalents$1.33B$1.48B$1.94B$2.45B$2.27B$1.63B$1.78B$2.11B
Short-term investments$200.00M$200.00M—$0————
Receivables$1.69B$1.57B$1.51B$1.41B$1.54B$1.54B$1.36B$1.32B
Inventory$2.54B$2.57B$2.55B$2.46B$2.46B$2.44B$2.37B$2.31B
Current assets$6.29B$6.36B$6.47B$6.77B$6.58B$5.92B$5.88B$5.99B
PP&E, net$3.78B$3.76B$3.72B$3.69B$3.60B$3.54B$3.44B$3.39B
Goodwill$2.89B$2.77B$2.78B$2.77B$2.76B$2.76B$2.72B$2.72B
Intangibles$850.00M$918.00M$959.00M$998.00M$1.04B$1.07B$1.08B$1.13B
Total assets$15.09B$15.08B$15.15B$15.49B$15.16B$14.48B$14.10B$14.24B
Current liabilities$2.68B$2.06B$2.05B$2.17B$1.81B$3.37B$3.38B$3.41B
Short-term debt$750.00M——$0$0$1.35B$1.35B$1.35B
Long-term debt$8.30B$9.05B$9.04B$9.04B$7.07B$5.23B$5.23B$5.22B
Total debt$9.05B$9.05B$9.04B$9.04B$7.07B$6.58B$6.58B$6.57B
Total liabilities$11.79B$11.93B$11.92B$12.07B$9.76B$9.50B$9.44B$9.47B
Shareholders' equity$3.30B$3.15B$3.23B$3.42B$5.40B$4.98B$4.66B$4.77B
Net debt$7.72B$7.57B$7.10B$6.59B$4.80B$4.95B$4.79B$4.46B
Shares outstanding407.49M414.15M420.35M424.93M441.46M443.95M446.04M448.47M
Cash flow statement
Operating cash flow$824.00M$655.00M$401.00M$893.00M$936.00M$605.00M$515.00M$905.00M
Capital expenditure$107.00M$117.00M$110.00M$161.00M$138.00M$146.00M$178.00M$216.00M
Free cash flow$717.00M$538.00M$291.00M$732.00M$798.00M$459.00M$337.00M$689.00M
Investing cash flow-$262.00M-$300.00M-$87.00M-$166.00M-$168.00M-$212.00M-$203.00M$126.00M
Financing cash flow-$718.00M-$813.00M-$840.00M-$495.00M-$134.00M-$564.00M-$677.00M-$745.00M
Depreciation & amortization$119.00M$119.00M$119.00M$122.00M$122.00M$124.00M$119.00M$123.00M
Stock-based compensation$27.00M$26.00M$25.00M$22.00M$22.00M$22.00M$17.00M$19.00M
Share buybacks$500.00M$584.00M$1.53B$2.06B$394.00M$338.00M$443.00M$553.00M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.